Startseite › Magenkrebs › New York › New York City
Klinische Studien zu Magenkrebs in New York City, NY
31 Studien zu Magenkrebs suchen Teilnehmer an Standorten in und um New York City (im Umkreis von ca. 30 Meilen). Öffnen Sie eine Studie, um Teilnahmevoraussetzungen und Kontaktdaten des Studienteams zu sehen.
Offizieller Studientext (Englisch)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Teilnehmer gesuchtBeobachtungsstudieGesunde Freiwillige willkommen
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Teilnehmer gesuchtPhase 2
- Memorial Sloan Kettering Hospital, New York
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Teilnehmer gesuchtPhase 2/3
- Memorial Sloan Kettering Cancer Center, New York
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
Teilnehmer gesuchtPhase 3
- Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
Teilnehmer gesuchtPhase 2/3
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York
- Rockefeller Outpatient Pavilion (53rd Street), New York
- Memorial Sloan Kettering Cancer Center - Main Campus, New York
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
Teilnehmer gesuchtPhase 2
- Research Site, New York
A Study of Cadonilimab Combined With Chemotherapy in People With Gastric or Gastroesophageal Junction Cancer
Teilnehmer gesuchtPhase 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Teilnehmer gesuchtPhase 1
- New York University (NYU) Langone Medical Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Teilnehmer gesuchtPhase 1
- New York University (NYU) Clinical Cancer Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Teilnehmer gesuchtPhase 1/2
- Columbia University, New York
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
Teilnehmer gesuchtPhase 3
- Icahn School of Medicine at Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma
Teilnehmer gesuchtPhase 1/2
- Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Teilnehmer gesuchtPhase 1
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Teilnehmer gesuchtPhase 3
- Research Site, New York
- Research Site, New York
- Research Site, New York
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Teilnehmer gesuchtPhase 1
- Icahn School of Medicine at Mount Sinai, New York
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Teilnehmer gesuchtPhase 1/2
- Memorial Sloan Kettering Hospital, New York
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Teilnehmer gesuchtPhase 1
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Teilnehmer gesuchtPhase 3
- Memorial Sloan Kettering Cancer Center - MAIN, New York
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Teilnehmer gesuchtPhase 1/2
- Mt. Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Teilnehmer gesuchtPhase 1
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
- Icahn School of Medicine at Mount Sinai, New York
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Teilnehmer gesuchtPhase 2
- Memorial Sloan Kettering Cancer Center, New York
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Teilnehmer gesuchtPhase 1
- North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists, New York
- Columbia University Irving Medical Center, New York
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
Teilnehmer gesuchtPhase 1
- New York Medicine-New York-Presbyterian Hospital, New York
- Montefiore Medical Center - Montefiore Hospital, New York
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Teilnehmer gesuchtPhase 2
- Research Site, New York
Brodalumab in the Treatment of Immune-Related Adverse Events
Teilnehmer gesuchtPhase 1
- Columbia University Irving Medical Center, New York
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Teilnehmer gesuchtPhase 1/2
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
Teilnehmer gesuchtPhase 1
- NYU Langone, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study Collecting Health Information to Understand and Prevent Gastric Cancer
Teilnehmer gesuchtBeobachtungsstudieGesunde Freiwillige willkommen
- Memorial Sloan Kettering Cancer Center (All protocol activites), New York
Avutometinib and Defactinib in Diffuse Gastric Cancer
Teilnehmer gesuchtPhase 2
- Columbia University Irving Medical Center, New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Teilnehmer gesuchtBeobachtungsstudie
- Massive Bio SYNERGY-AI site, New York
Comprehensive Outcomes for After Cancer Health
Teilnehmer gesuchtGesunde Freiwillige willkommen
- Memorial Sloan Kettering Cancer Center, New York
Magenkrebs-Studien in anderen Städten
- Houston, TX42 Studien
- Boston, MA32 Studien
- Nashville, TN28 Studien
- Baldwin Park, CA22 Studien
- Los Angeles, CA22 Studien
- Arlington, VA20 Studien
- Dallas, TX19 Studien
- San Antonio, TX19 Studien
- St. Louis, MO18 Studien
- Grand Rapids, MI18 Studien
- Chicago, IL16 Studien
- Washington, DC16 Studien
Weitere Studien in New York City
- Brustkrebs136 Studien
- Nichtkleinzelliges Lungenkarzinom121 Studien
- Krebs (alle Arten)109 Studien
- Prostatakrebs103 Studien
- Metastasierender Krebs93 Studien
- Kolorektales Karzinom78 Studien
- Eierstockkrebs69 Studien
- Lungenkrebs60 Studien
- Multiples Myelom60 Studien
- Bauchspeicheldrüsenkrebs60 Studien
- Endometriumkarzinom52 Studien
- Akute myeloische Leukämie51 Studien
Quelle: ClinicalTrials.gov, Daten abgerufen am 06.10.2026. Jede Studie legt ihre eigenen Teilnahmevoraussetzungen fest; das Studienteam entscheidet über die Zulassung.